{"protocolSection": {"identificationModule": {"nctId": "NCT00968201", "orgStudyIdInfo": {"id": "0476-072"}, "secondaryIdInfos": [{"id": "2009_651"}], "organization": {"fullName": "Organon and Co", "class": "INDUSTRY"}, "briefTitle": "Chronic Asthma Study in 2- to 5-Year-Old Patients (MK0476-072 )", "officialTitle": "A Multicenter, Double-Blind, Randomized, Parallel-Group Chronic Asthma Study Comparing Montelukast With Placebo in 2- to 5-Year-Old Patients"}, "statusModule": {"statusVerifiedDate": "2022-02", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "1997-12"}, "primaryCompletionDateStruct": {"date": "2001-03", "type": "ACTUAL"}, "completionDateStruct": {"date": "2001-03", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-08-27", "studyFirstSubmitQcDate": "2009-08-27", "studyFirstPostDateStruct": {"date": "2009-08-28", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2009-09-15", "resultsFirstSubmitQcDate": "2010-07-06", "resultsFirstPostDateStruct": {"date": "2010-08-03", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2022-02-01", "lastUpdatePostDateStruct": {"date": "2022-02-03", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Organon and Co", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "A study in 2-5 year old children to evaluate the safety and tolerability of montelukast and placebo administered once daily at bed time."}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 689, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "1", "type": "EXPERIMENTAL", "description": "Montelukast", "interventionNames": ["Drug: montelukast sodium"]}, {"label": "2", "type": "PLACEBO_COMPARATOR", "description": "Placebo", "interventionNames": ["Drug: Comparator: Placebo"]}], "interventions": [{"type": "DRUG", "name": "montelukast sodium", "description": "one chewable 4-mg montelukast tablet, once daily at bedtime for 12 weeks", "armGroupLabels": ["1"]}, {"type": "DRUG", "name": "Comparator: Placebo", "description": "one chewable placebo tablet, once daily at bedtime for 12 weeks", "armGroupLabels": ["2"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number of Patients With Clinical Adverse Experiences (CAE) Reported by Patients - Base Study", "description": "An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product", "timeFrame": "12 weeks of treatment"}], "secondaryOutcomes": [{"measure": "Number of Patients With Drug-related CAEs Reported by Patients - Base Study", "description": "Patients with drug-related (as assessed by an investigator who is a qualified physician according to his/her best clinical judgment) CAEs", "timeFrame": "12 weeks of treatment"}, {"measure": "Number of Patients With Serious CAEs Reported by Patients - Base Study", "description": "Serious CAEs are any AEs occurring at any dose that; Results in death; or Is life threatening; or Results in a persistent or significant disability/incapacity; or Results in or prolongs an existing inpatient hospitalization; or Is a congenital anomaly/birth defect; or Is a cancer; or Is an overdose", "timeFrame": "12 weeks of treatment"}, {"measure": "Number of Patients With Serious Drug-related CAEs Reported by Patients - Base Study", "description": "Patients who reported serious drug-related CAEs during 12 weeks of treatment", "timeFrame": "12 weeks of treatment"}, {"measure": "Number of Patients Who Were Discontinued Due to CAEs - Base Study", "description": "Patients who were discontinued due to CAEs during 12 weeks of treatment", "timeFrame": "12 weeks of treatment"}, {"measure": "Number of Patients Who Were Discontinued Due to Drug-related CAEs - Base Study", "description": "Patients who were discontinued due to drug-related CAEs during 12 weeks of treatment", "timeFrame": "12 weeks of treatment"}, {"measure": "Number of Patients Who Were Discontinued Due to Serious CAEs - Base Study", "description": "Patients who were discontinued due to serious CAEs during 12 weeks of treatment", "timeFrame": "12 weeks of treatment"}, {"measure": "Number of Patients With Laboratory Adverse Experiences (LAEs) - Base Study", "description": "A laboratory adverse experience (LAE) is defined as any unfavorable and unintended change in the chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product", "timeFrame": "12 weeks of treatment"}, {"measure": "Number of Patients With Drug-related Laboratory Adverse Experiences (LAEs) - Base Study", "description": "Patients with drug-related (as assessed by an investigator who is a qualified physician according to his/her best clinical judgment) LAEs", "timeFrame": "12 weeks of treatment"}, {"measure": "Number of Patients Who Were Discontinued Due to LAEs - Base Study", "description": "Patients who were discontinued due to LAEs during 12 weeks of treatment", "timeFrame": "12 weeks of treatment"}, {"measure": "Number of Patients Who Were Discontinued Due to Drug-related LAEs - Base Study", "description": "Patients who were discontinued due to drug-related LAEs during 12 weeks of treatment", "timeFrame": "12 weeks of treatment"}, {"measure": "Number of Patients With Clinical Adverse Experiences (CAE) Reported by Patients - Extension", "description": "An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product", "timeFrame": "up to 2.8 years"}, {"measure": "Number of Patients With Drug-related CAEs Reported by Patients - Extension", "description": "Patients with drug-related (as assessed by an investigator who is a qualified physician according to his/her best clinical judgment) CAEs", "timeFrame": "up to 2.8 years"}, {"measure": "Number of Patients With Serious CAEs Reported by Patients - Extension", "description": "Serious CAEs are any AEs occurring at any dose that; Results in death; or Is life threatening; or Results in a persistent or significant disability/incapacity; or Results in or prolongs an existing inpatient hospitalization; or Is a congenital anomaly/birth defect; or Is a cancer; or Is an overdose", "timeFrame": "up to 2.8 years"}, {"measure": "Number of Patients With Serious Drug-related CAEs Reported by Patients - Extension", "description": "Patients who reported serious drug-related CAEs up to 2.8 years of\n\ntreatment", "timeFrame": "up to 2.8 years"}, {"measure": "Number of Patients Who Were Discontinued Due to CAEs - Extension", "description": "Patients who were discontinued due to CAEs up to 2.8 years of treatment", "timeFrame": "up to 2.8 years"}, {"measure": "Number of Patients Who Were Discontinued Due to Drug-related CAEs - Extension", "description": "Patients who were discontinued due to drug-related CAEs with up to 2.8 years of treatment", "timeFrame": "up to 2.8 years"}, {"measure": "Number of Patients Who Were Discontinued Due to Serious CAEs - Extension", "description": "Patients who were discontinued due to serious CAEs with up to 2.8 years of treatment", "timeFrame": "up to 2.8 years"}, {"measure": "Number of Patients Who Were Discontinued Due to Serious Drug-related CAEs - Extension", "description": "Patients who were discontinued due to serious drug-related CAEs with up to 2.8 years of treatment", "timeFrame": "up to 2.8 years"}, {"measure": "Number of Patients With Laboratory Adverse Experiences (LAEs) - Extension", "description": "A laboratory adverse experience (LAE) is defined as any unfavorable and unintended change in the chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product", "timeFrame": "up to 2.8 years"}, {"measure": "Number of Patients With Drug-related Laboratory Adverse Experiences (LAEs) - Extension", "description": "Patients with drug-related (as assessed by an investigator who is a qualified physician according to his/her best clinical judgment) LAEs", "timeFrame": "up to 2.8 years"}, {"measure": "Number of Patients With Serious LAEs - Extension", "description": "Serious LAEs are any LAEs occurring at any dose that; Results in death; or Is life threatening; or Results in a persistent or significant disability/incapacity; or Results in or prolongs an existing inpatient hospitalization; or Is a congenital anomaly/birth defect; or Is a cancer; or Is an overdose", "timeFrame": "up to 2.8 years"}, {"measure": "Number of Patients With Serious Drug-related Laboratory Adverse Experiences (LAEs) - Extension", "description": "Patients who reported serious drug-related LAEs up to 2.8 years of treatment", "timeFrame": "up to 2.8 years"}, {"measure": "Number of Patients Who Were Discontinued Due to LAEs - Extension", "description": "Patients who were discontinued due to LAEs up to 2.8 years of treatment", "timeFrame": "up to 2.8 years"}, {"measure": "Number of Patients Who Were Discontinued Due to Drug-related LAEs - Extension", "description": "Patients who were discontinued due to drug-related LAEs with up to 2.8 years of treatment", "timeFrame": "up to 2.8 years"}, {"measure": "Number of Patients Who Were Discontinued Due to Serious LAEs - Extension", "description": "Patients who were discontinued due to serious LAEs with up to 2.8 years of treatment", "timeFrame": "up to 2.8 years"}, {"measure": "Number of Patients Who Were Discontinued Due to Serious Drug-related LAEs - Extension", "description": "Patients who were discontinued due to serious drug-related LAEs with up to 2.8 years of treatment", "timeFrame": "up to 2.8 years"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patient has history of physician diagnosed asthma\n* Patient is in otherwise good stable health\n* Patient is able to chew a tablet\n\nExclusion Criteria:\n\n* Patient is hospitalized\n* Patient and/or parent of guardian intends to move or vacation away from home during the course of the study\n* Patient had any major surgical procedure within 4 weeks before the study\n* Patient had active sinus disease within 3 weeks before the study\n* Patient had required intubation for asthma in the past\n* Patient required a visit to the emergency room due to an asthma exacerbation, or has been hospitalized for asthma with in 1 month prior to the study\n* Patient had used inhaled, nebulized, intramuscular, or intravenous steroids with in 1 month before study", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "2 Years", "maximumAge": "5 Years", "stdAges": ["CHILD"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Monitor", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}, "referencesModule": {"references": [{"pmid": "11533366", "type": "RESULT", "citation": "Knorr B, Franchi LM, Bisgaard H, Vermeulen JH, LeSouef P, Santanello N, Michele TM, Reiss TF, Nguyen HH, Bratton DL. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics. 2001 Sep;108(3):E48. doi: 10.1542/peds.108.3.e48."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Base Study: Patients who required excluded medication and those who did not meet a minimum predefined level of asthma symptoms and \u03b2-agonist use during run-in (Period I) were excluded from randomization (Period II).\n\nExtension Study (Period III): Patients who did not complete Visit 9 of Base Study were not eligible for the optional Extension.", "recruitmentDetails": "Base Study: 93 sites in the United States (US) and other countries in Africa, Australia, Europe, North America, and South America. Therapy period: Dec-1997 to Mar-1999.\n\nExtension Study: 75 sites in the US and other countries in Africa, Australia, Europe, North America, and South America. Therapy period: Mar-1998 to Mar-2001.", "groups": [{"id": "FG000", "title": "Placebo", "description": "Montelukast matching-image placebo chewable tablet orally once daily at bedtime for 12 weeks."}, {"id": "FG001", "title": "Usual Care", "description": "\"Usual care,\" defined as inhaled/nebulized cromolyn or inhaled/nebulized corticosteroids according to the usual clinical practice of the investigator, for up to 2.8 years. Some patients receiving placebo in Period II were switched to usual care in the Extension Study, and some\n\npatients receiving montelukast in Period II were switched to usual care in the Extension Study.\n\nPatients already using corticosteroids during Period I and II continued on the same medication and dose throughout Period II. Their dose was not increased if they were allocated to the \"usual care\" treatment group in Period III."}, {"id": "FG002", "title": "Montelukast", "description": "Base Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for 12 weeks.\n\nExtension Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for up to 2.8 years. Some patients receiving placebo in Period II were switched to montelukast in the Extension Study, and some patients receiving montelukast in Period II continued on montelukast in the Extension Study. One hundred sixty-seven patients were switched to the 5 mg chewable tablet at\n\ntheir first visit after turning 6 years old. The 4 mg and 5 mg chewable tablet data are pooled together."}], "periods": [{"title": "Base Study - (Period II)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "Includes patients who completed Period I (2-week placebo run-in) and were randomized to placebo.", "numSubjects": "228"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "comment": "Includes patients who completed Period I (2-week placebo run-in) and were randomized to montelukast.", "numSubjects": "461"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "comment": "Patients completing Period II were eligible to enter the optional Period III", "numSubjects": "202"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "comment": "Patients completing Period II were eligible to enter the optional Period III", "numSubjects": "416"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "26"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "45"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "16"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "7"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "12"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "12"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "8"}]}, {"type": "Site Error", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}]}]}, {"title": "Extension Study - (Period III)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "comment": "Eligible Patients who completed Period II and entered the optional Extension Study (Period III)", "numSubjects": "157"}, {"groupId": "FG002", "comment": "Eligible Patients who completed Period II and entered the optional Extension Study (Period III)", "numSubjects": "364"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "33"}, {"groupId": "FG002", "numSubjects": "84"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "124"}, {"groupId": "FG002", "numSubjects": "280"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "22"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "7"}, {"groupId": "FG002", "numSubjects": "13"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "17"}, {"groupId": "FG002", "numSubjects": "14"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "20"}, {"groupId": "FG002", "numSubjects": "40"}]}, {"type": "Patient Relocated", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Noncompliance", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "3"}]}, {"type": "Other", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "2"}]}, {"type": "Study Terminated for Admin Reasons", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "74"}, {"groupId": "FG002", "numSubjects": "185"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Placebo", "description": "Montelukast matching-image placebo chewable tablet orally once daily at bedtime for 12 weeks."}, {"id": "BG001", "title": "Montelukast", "description": "Base Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for 12 weeks."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "228"}, {"groupId": "BG001", "value": "461"}, {"groupId": "BG002", "value": "689"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "3.62", "spread": "1.10"}, {"groupId": "BG001", "value": "3.58", "spread": "1.11"}, {"groupId": "BG002", "value": "3.59", "spread": "1.10"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "97"}, {"groupId": "BG001", "value": "189"}, {"groupId": "BG002", "value": "286"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "131"}, {"groupId": "BG001", "value": "272"}, {"groupId": "BG002", "value": "403"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Number of Patients With Clinical Adverse Experiences (CAE) Reported by Patients - Base Study", "description": "An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product", "populationDescription": "All patients who took study medication were included in the analysis.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "12 weeks of treatment", "groups": [{"id": "OG000", "title": "Placebo", "description": "Montelukast matching-image placebo chewable tablet orally once daily at bedtime for 12 weeks."}, {"id": "OG001", "title": "Montelukast", "description": "Base Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "228"}, {"groupId": "OG001", "value": "461"}]}], "classes": [{"title": "With CAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "202"}, {"groupId": "OG001", "value": "406"}]}]}, {"title": "Without CAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "55"}]}]}]}, {"type": "SECONDARY", "title": "Number of Patients With Drug-related CAEs Reported by Patients - Base Study", "description": "Patients with drug-related (as assessed by an investigator who is a qualified physician according to his/her best clinical judgment) CAEs", "populationDescription": "All patients who took study medication were included in the analysis.\n\nDrug relationship for 1 patient in the Placebo group should have been listed as definitely not drug related.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "12 weeks of treatment", "groups": [{"id": "OG000", "title": "Placebo", "description": "Montelukast matching-image placebo chewable tablet orally once daily at bedtime for 12 weeks."}, {"id": "OG001", "title": "Montelukast", "description": "Base Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "228"}, {"groupId": "OG001", "value": "461"}]}], "classes": [{"title": "With Drug-Related CAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "19"}]}]}, {"title": "Without Drug-Related CAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "219"}, {"groupId": "OG001", "value": "442"}]}]}]}, {"type": "SECONDARY", "title": "Number of Patients With Serious CAEs Reported by Patients - Base Study", "description": "Serious CAEs are any AEs occurring at any dose that; Results in death; or Is life threatening; or Results in a persistent or significant disability/incapacity; or Results in or prolongs an existing inpatient hospitalization; or Is a congenital anomaly/birth defect; or Is a cancer; or Is an overdose", "populationDescription": "All patients who took study medication were included in the analysis.\n\nA serious CAE (study drug overdose) prior to randomization in the Placebo group is not included in this number", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "12 weeks of treatment", "groups": [{"id": "OG000", "title": "Placebo", "description": "Montelukast matching-image placebo chewable tablet orally once daily at bedtime for 12 weeks."}, {"id": "OG001", "title": "Montelukast", "description": "Base Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "228"}, {"groupId": "OG001", "value": "461"}]}], "classes": [{"title": "With Serious CAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "17"}]}]}, {"title": "Without Serious CAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "219"}, {"groupId": "OG001", "value": "444"}]}]}]}, {"type": "SECONDARY", "title": "Number of Patients With Serious Drug-related CAEs Reported by Patients - Base Study", "description": "Patients who reported serious drug-related CAEs during 12 weeks of treatment", "populationDescription": "All patients who took study medication were included in the analysis.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "12 weeks of treatment", "groups": [{"id": "OG000", "title": "Placebo", "description": "Montelukast matching-image placebo chewable tablet orally once daily at bedtime for 12 weeks."}, {"id": "OG001", "title": "Montelukast", "description": "Base Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "228"}, {"groupId": "OG001", "value": "461"}]}], "classes": [{"title": "With Serious Drug-related CAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "Without Serious Drug-related CAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "228"}, {"groupId": "OG001", "value": "459"}]}]}]}, {"type": "SECONDARY", "title": "Number of Patients Who Were Discontinued Due to CAEs - Base Study", "description": "Patients who were discontinued due to CAEs during 12 weeks of treatment", "populationDescription": "All patients who took study medication were included in the analysis.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "12 weeks of treatment", "groups": [{"id": "OG000", "title": "Placebo", "description": "Montelukast matching-image placebo chewable tablet orally once daily at bedtime for 12 weeks."}, {"id": "OG001", "title": "Montelukast", "description": "Base Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "228"}, {"groupId": "OG001", "value": "461"}]}], "classes": [{"title": "Discontinued Due to CAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "16"}]}]}, {"title": "Did Not Discontinue Due to CAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "221"}, {"groupId": "OG001", "value": "445"}]}]}]}, {"type": "SECONDARY", "title": "Number of Patients Who Were Discontinued Due to Drug-related CAEs - Base Study", "description": "Patients who were discontinued due to drug-related CAEs during 12 weeks of treatment", "populationDescription": "All patients who took study medication were included in the analysis.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "12 weeks of treatment", "groups": [{"id": "OG000", "title": "Placebo", "description": "Montelukast matching-image placebo chewable tablet orally once daily at bedtime for 12 weeks."}, {"id": "OG001", "title": "Montelukast", "description": "Base Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "228"}, {"groupId": "OG001", "value": "461"}]}], "classes": [{"title": "Discontinued Due to Drug-related CAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "Did Not Discontinue Due to Drug-related CAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "227"}, {"groupId": "OG001", "value": "459"}]}]}]}, {"type": "SECONDARY", "title": "Number of Patients Who Were Discontinued Due to Serious CAEs - Base Study", "description": "Patients who were discontinued due to serious CAEs during 12 weeks of treatment", "populationDescription": "All patients who took study medication were included in the analysis.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "12 weeks of treatment", "groups": [{"id": "OG000", "title": "Placebo", "description": "Montelukast matching-image placebo chewable tablet orally once daily at bedtime for 12 weeks."}, {"id": "OG001", "title": "Montelukast", "description": "Base Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "228"}, {"groupId": "OG001", "value": "461"}]}], "classes": [{"title": "Discontinued Due to Serious CAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "8"}]}]}, {"title": "Did Not Discontinue Due to Serious CAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "226"}, {"groupId": "OG001", "value": "453"}]}]}]}, {"type": "SECONDARY", "title": "Number of Patients With Laboratory Adverse Experiences (LAEs) - Base Study", "description": "A laboratory adverse experience (LAE) is defined as any unfavorable and unintended change in the chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product", "populationDescription": "All patients who took study medication and had at least one laboratory test post baseline were included in the analysis.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "12 weeks of treatment", "groups": [{"id": "OG000", "title": "Placebo", "description": "Montelukast matching-image placebo chewable tablet orally once daily at bedtime for 12 weeks."}, {"id": "OG001", "title": "Montelukast", "description": "Base Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "224"}, {"groupId": "OG001", "value": "451"}]}], "classes": [{"title": "With LAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "16"}]}]}, {"title": "Without LAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "212"}, {"groupId": "OG001", "value": "435"}]}]}]}, {"type": "SECONDARY", "title": "Number of Patients With Drug-related Laboratory Adverse Experiences (LAEs) - Base Study", "description": "Patients with drug-related (as assessed by an investigator who is a qualified physician according to his/her best clinical judgment) LAEs", "populationDescription": "All patients who took study medication and had at least one laboratory test post baseline were included in the analysis.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "12 weeks of treatment", "groups": [{"id": "OG000", "title": "Placebo", "description": "Montelukast matching-image placebo chewable tablet orally once daily at bedtime for 12 weeks."}, {"id": "OG001", "title": "Montelukast", "description": "Base Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "224"}, {"groupId": "OG001", "value": "451"}]}], "classes": [{"title": "With Drug-Related LAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "7"}]}]}, {"title": "Without Drug-Related LAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "223"}, {"groupId": "OG001", "value": "444"}]}]}]}, {"type": "SECONDARY", "title": "Number of Patients Who Were Discontinued Due to LAEs - Base Study", "description": "Patients who were discontinued due to LAEs during 12 weeks of treatment", "populationDescription": "All patients who took study medication and had at least one laboratory test post baseline were included in the analysis.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "12 weeks of treatment", "groups": [{"id": "OG000", "title": "Placebo", "description": "Montelukast matching-image placebo chewable tablet orally once daily at bedtime for 12 weeks."}, {"id": "OG001", "title": "Montelukast", "description": "Base Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "224"}, {"groupId": "OG001", "value": "451"}]}], "classes": [{"title": "Discontinued Due to LAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Did Not Discontinue Due to LAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "223"}, {"groupId": "OG001", "value": "451"}]}]}]}, {"type": "SECONDARY", "title": "Number of Patients Who Were Discontinued Due to Drug-related LAEs - Base Study", "description": "Patients who were discontinued due to drug-related LAEs during 12 weeks of treatment", "populationDescription": "All patients who took study medication and had at least one laboratory test post baseline were included in the analysis.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "12 weeks of treatment", "groups": [{"id": "OG000", "title": "Placebo", "description": "Montelukast matching-image placebo chewable tablet orally once daily at bedtime for 12 weeks."}, {"id": "OG001", "title": "Montelukast", "description": "Base Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "224"}, {"groupId": "OG001", "value": "451"}]}], "classes": [{"title": "Discontinued Due to Drug-related LAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Did Not Discontinue Due to Drug-related LAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "223"}, {"groupId": "OG001", "value": "451"}]}]}]}, {"type": "SECONDARY", "title": "Number of Patients With Clinical Adverse Experiences (CAE) Reported by Patients - Extension", "description": "An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product", "populationDescription": "All patients who took study medication were included in the analysis.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "up to 2.8 years", "groups": [{"id": "OG000", "title": "Usual Care", "description": "\"Usual care,\" defined as inhaled/nebulized cromolyn or inhaled/nebulized corticosteroids according to the usual clinical practice of the investigator, for up to 2.8 years. Some patients receiving placebo in Period II were switched to usual care in the Extension Study, and some patients receiving montelukast in Period II were switched to usual care in the Extension Study. Patients already using corticosteroids during Period I and II continued on the same medication and dose throughout Period II. Their dose was not increased if they were allocated to the \"usual care\" treatment group in Period III."}, {"id": "OG001", "title": "Montelukast", "description": "Extension Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for up to 2.8 years. Some patients receiving placebo in Period II were switched to montelukast in the Extension Study, and some patients receiving montelukast in Period II continued on montelukast in the Extension Study. One hundred sixty-seven patients were switched to the 5 mg chewable tablet at their first visit after turning 6 years old. The 4 mg and 5 mg chewable tablet data are pooled together."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "157"}, {"groupId": "OG001", "value": "364"}]}], "classes": [{"title": "With CAE", "categories": [{"measurements": [{"groupId": "OG000", "value": "149"}, {"groupId": "OG001", "value": "353"}]}]}, {"title": "Without CAE", "categories": [{"measurements": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "11"}]}]}]}, {"type": "SECONDARY", "title": "Number of Patients With Drug-related CAEs Reported by Patients - Extension", "description": "Patients with drug-related (as assessed by an investigator who is a qualified physician according to his/her best clinical judgment) CAEs", "populationDescription": "All patients who took study medication were included in the analysis.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "up to 2.8 years", "groups": [{"id": "OG000", "title": "Usual Care", "description": "\"Usual care,\" defined as inhaled/nebulized cromolyn or inhaled/nebulized corticosteroids according to the usual clinical practice of the investigator, for up to 2.8 years. Some patients receiving placebo in Period II were switched to usual care in the Extension Study, and some patients receiving montelukast in Period II were switched to usual care in the Extension Study. Patients already using corticosteroids during Period I and II continued on the same medication and dose throughout Period II. Their dose was not increased if they were allocated to the \"usual care\" treatment group in Period III."}, {"id": "OG001", "title": "Montelukast", "description": "Extension Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for up to 2.8 years. Some patients receiving placebo in Period II were switched to montelukast in the Extension Study, and some patients receiving montelukast in Period II continued on montelukast in the Extension Study. One hundred sixty-seven patients were switched to the 5 mg chewable tablet at their first visit after turning 6 years old. The 4 mg and 5 mg chewable tablet data are pooled together."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "157"}, {"groupId": "OG001", "value": "364"}]}], "classes": [{"title": "With Drug-related CAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "14"}]}]}, {"title": "Without Drug-related CAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "155"}, {"groupId": "OG001", "value": "350"}]}]}]}, {"type": "SECONDARY", "title": "Number of Patients With Serious CAEs Reported by Patients - Extension", "description": "Serious CAEs are any AEs occurring at any dose that; Results in death; or Is life threatening; or Results in a persistent or significant disability/incapacity; or Results in or prolongs an existing inpatient hospitalization; or Is a congenital anomaly/birth defect; or Is a cancer; or Is an overdose", "populationDescription": "All patients who took study medication were included in the analysis.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "up to 2.8 years", "groups": [{"id": "OG000", "title": "Usual Care", "description": "\"Usual care,\" defined as inhaled/nebulized cromolyn or inhaled/nebulized corticosteroids according to the usual clinical practice of the investigator, for up to 2.8 years. Some patients receiving placebo in Period II were switched to usual care in the Extension Study, and some patients receiving montelukast in Period II were switched to usual care in the Extension Study. Patients already using corticosteroids during Period I and II continued on the same medication and dose throughout Period II. Their dose was not increased if they were allocated to the \"usual care\" treatment group in Period III."}, {"id": "OG001", "title": "Montelukast", "description": "Extension Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for up to 2.8 years. Some patients receiving placebo in Period II were switched to montelukast in the Extension Study, and some patients receiving montelukast in Period II continued on montelukast in the Extension Study. One hundred sixty-seven patients were switched to the 5 mg chewable tablet at their first visit after turning 6 years old. The 4 mg and 5 mg chewable tablet data are pooled together."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "157"}, {"groupId": "OG001", "value": "364"}]}], "classes": [{"title": "With Serious CAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "38"}]}]}, {"title": "Without Serious CAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "142"}, {"groupId": "OG001", "value": "326"}]}]}]}, {"type": "SECONDARY", "title": "Number of Patients With Serious Drug-related CAEs Reported by Patients - Extension", "description": "Patients who reported serious drug-related CAEs up to 2.8 years of\n\ntreatment", "populationDescription": "All patients who took study medication were included in the analysis.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "up to 2.8 years", "groups": [{"id": "OG000", "title": "Usual Care", "description": "\"Usual care,\" defined as inhaled/nebulized cromolyn or inhaled/nebulized corticosteroids according to the usual clinical practice of the investigator, for up to 2.8 years. Some patients receiving placebo in Period II were switched to usual care in the Extension Study, and some patients receiving montelukast in Period II were switched to usual care in the Extension Study. Patients already using corticosteroids during Period I and II continued on the same medication and dose throughout Period II. Their dose was not increased if they were allocated to the \"usual care\" treatment group in Period III."}, {"id": "OG001", "title": "Montelukast", "description": "Extension Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for up to 2.8 years. Some patients receiving placebo in Period II were switched to montelukast in the Extension Study, and some patients receiving montelukast in Period II continued on montelukast in the Extension Study. One hundred sixty-seven patients were switched to the 5 mg chewable tablet at their first visit after turning 6 years old. The 4 mg and 5 mg chewable tablet data are pooled together."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "157"}, {"groupId": "OG001", "value": "364"}]}], "classes": [{"title": "With Serious Drug-related CAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "4"}]}]}, {"title": "Without Serious Drug-related CAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "157"}, {"groupId": "OG001", "value": "360"}]}]}]}, {"type": "SECONDARY", "title": "Number of Patients Who Were Discontinued Due to CAEs - Extension", "description": "Patients who were discontinued due to CAEs up to 2.8 years of treatment", "populationDescription": "All patients who took study medication were included in the analysis.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "up to 2.8 years", "groups": [{"id": "OG000", "title": "Usual Care", "description": "\"Usual care,\" defined as inhaled/nebulized cromolyn or inhaled/nebulized corticosteroids according to the usual clinical practice of the investigator, for up to 2.8 years. Some patients receiving placebo in Period II were switched to usual care in the Extension Study, and some patients receiving montelukast in Period II were switched to usual care in the Extension Study. Patients already using corticosteroids during Period I and II continued on the same medication and dose throughout Period II. Their dose was not increased if they were allocated to the \"usual care\" treatment group in Period III."}, {"id": "OG001", "title": "Montelukast", "description": "Extension Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for up to 2.8 years. Some patients receiving placebo in Period II were switched to montelukast in the Extension Study, and some patients receiving montelukast in Period II continued on montelukast in the Extension Study. One hundred sixty-seven patients were switched to the 5 mg chewable tablet at their first visit after turning 6 years old. The 4 mg and 5 mg chewable tablet data are pooled together."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "157"}, {"groupId": "OG001", "value": "364"}]}], "classes": [{"title": "Discontinued Due to CAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "18"}]}]}, {"title": "Did Not Discontinue Due to CAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "152"}, {"groupId": "OG001", "value": "346"}]}]}]}, {"type": "SECONDARY", "title": "Number of Patients Who Were Discontinued Due to Drug-related CAEs - Extension", "description": "Patients who were discontinued due to drug-related CAEs with up to 2.8 years of treatment", "populationDescription": "All patients who took study medication were included in the analysis.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "up to 2.8 years", "groups": [{"id": "OG000", "title": "Usual Care", "description": "\"Usual care,\" defined as inhaled/nebulized cromolyn or inhaled/nebulized corticosteroids according to the usual clinical practice of the investigator, for up to 2.8 years. Some patients receiving placebo in Period II were switched to usual care in the Extension Study, and some patients receiving montelukast in Period II were switched to usual care in the Extension Study. Patients already using corticosteroids during Period I and II continued on the same medication and dose throughout Period II. Their dose was not increased if they were allocated to the \"usual care\" treatment group in Period III."}, {"id": "OG001", "title": "Montelukast", "description": "Extension Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for up to 2.8 years. Some patients receiving placebo in Period II were switched to montelukast in the Extension Study, and some patients receiving montelukast in Period II continued on montelukast in the Extension Study. One hundred sixty-seven patients were switched to the 5 mg chewable tablet at their first visit after turning 6 years old. The 4 mg and 5 mg chewable tablet data are pooled together."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "157"}, {"groupId": "OG001", "value": "364"}]}], "classes": [{"title": "Discontinued Due to Drug-related CAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "Did Not Discontinue Due to Drug-related CAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "157"}, {"groupId": "OG001", "value": "362"}]}]}]}, {"type": "SECONDARY", "title": "Number of Patients Who Were Discontinued Due to Serious CAEs - Extension", "description": "Patients who were discontinued due to serious CAEs with up to 2.8 years of treatment", "populationDescription": "All patients who took study medication were included in the analysis.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "up to 2.8 years", "groups": [{"id": "OG000", "title": "Usual Care", "description": "\"Usual care,\" defined as inhaled/nebulized cromolyn or inhaled/nebulized corticosteroids according to the usual clinical practice of the investigator, for up to 2.8 years. Some patients receiving placebo in Period II were switched to usual care in the Extension Study, and some patients receiving montelukast in Period II were switched to usual care in the Extension Study. Patients already using corticosteroids during Period I and II continued on the same medication and dose throughout Period II. Their dose was not increased if they were allocated to the \"usual care\" treatment group in Period III."}, {"id": "OG001", "title": "Montelukast", "description": "Extension Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for up to 2.8 years. Some patients receiving placebo in Period II were switched to montelukast in the Extension Study, and some patients receiving montelukast in Period II continued on montelukast in the Extension Study. One hundred sixty-seven patients were switched to the 5 mg chewable tablet at their first visit after turning 6 years old. The 4 mg and 5 mg chewable tablet data are pooled together."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "157"}, {"groupId": "OG001", "value": "364"}]}], "classes": [{"title": "Discontinued Due to Serious CAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "9"}]}]}, {"title": "Did Not Discontinue Due to Serious CAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "156"}, {"groupId": "OG001", "value": "355"}]}]}]}, {"type": "SECONDARY", "title": "Number of Patients Who Were Discontinued Due to Serious Drug-related CAEs - Extension", "description": "Patients who were discontinued due to serious drug-related CAEs with up to 2.8 years of treatment", "populationDescription": "All patients who took study medication were included in the analysis.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "up to 2.8 years", "groups": [{"id": "OG000", "title": "Usual Care", "description": "\"Usual care,\" defined as inhaled/nebulized cromolyn or inhaled/nebulized corticosteroids according to the usual clinical practice of the investigator, for up to 2.8 years. Some patients receiving placebo in Period II were switched to usual care in the Extension Study, and some patients receiving montelukast in Period II were switched to usual care in the Extension Study. Patients already using corticosteroids during Period I and II continued on the same medication and dose throughout Period II. Their dose was not increased if they were allocated to the \"usual care\" treatment group in Period III."}, {"id": "OG001", "title": "Montelukast", "description": "Extension Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for up to 2.8 years. Some patients receiving placebo in Period II were switched to montelukast in the Extension Study, and some patients receiving montelukast in Period II continued on montelukast in the Extension Study. One hundred sixty-seven patients were switched to the 5 mg chewable tablet at their first visit after turning 6 years old. The 4 mg and 5 mg chewable tablet data are pooled together."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "157"}, {"groupId": "OG001", "value": "364"}]}], "classes": [{"title": "Discontinued Due to Serious Drug-related CAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Not Discontinued Due to Serious Drug-related CAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "157"}, {"groupId": "OG001", "value": "363"}]}]}]}, {"type": "SECONDARY", "title": "Number of Patients With Laboratory Adverse Experiences (LAEs) - Extension", "description": "A laboratory adverse experience (LAE) is defined as any unfavorable and unintended change in the chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product", "populationDescription": "All patients who took study medication were included in the analysis.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "up to 2.8 years", "groups": [{"id": "OG000", "title": "Usual Care", "description": "\"Usual care,\" defined as inhaled/nebulized cromolyn or inhaled/nebulized corticosteroids according to the usual clinical practice of the investigator, for up to 2.8 years. Some patients receiving placebo in Period II were switched to usual care in the Extension Study, and some patients receiving montelukast in Period II were switched to usual care in the Extension Study. Patients already using corticosteroids during Period I and II continued on the same medication and dose throughout Period II. Their dose was not increased if they were allocated to the \"usual care\" treatment group in Period III."}, {"id": "OG001", "title": "Montelukast", "description": "Extension Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for up to 2.8 years. Some patients receiving placebo in Period II were switched to montelukast in the Extension Study, and some patients receiving montelukast in Period II continued on montelukast in the Extension Study. One hundred sixty-seven patients were switched to the 5 mg chewable tablet at their first visit after turning 6 years old. The 4 mg and 5 mg chewable tablet data are pooled together."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "154"}, {"groupId": "OG001", "value": "357"}]}], "classes": [{"title": "With LAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "42"}]}]}, {"title": "Without LAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "140"}, {"groupId": "OG001", "value": "315"}]}]}]}, {"type": "SECONDARY", "title": "Number of Patients With Drug-related Laboratory Adverse Experiences (LAEs) - Extension", "description": "Patients with drug-related (as assessed by an investigator who is a qualified physician according to his/her best clinical judgment) LAEs", "populationDescription": "All patients who took study medication and had at least one laboratory test post baseline were included in the analysis.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "up to 2.8 years", "groups": [{"id": "OG000", "title": "Usual Care", "description": "\"Usual care,\" defined as inhaled/nebulized cromolyn or inhaled/nebulized corticosteroids according to the usual clinical practice of the investigator, for up to 2.8 years. Some patients receiving placebo in Period II were switched to usual care in the Extension Study, and some patients receiving montelukast in Period II were switched to usual care in the Extension Study. Patients already using corticosteroids during Period I and II continued on the same medication and dose throughout Period II. Their dose was not increased if they were allocated to the \"usual care\" treatment group in Period III."}, {"id": "OG001", "title": "Montelukast", "description": "Extension Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for up to 2.8 years. Some patients receiving placebo in Period II were switched to montelukast in the Extension Study, and some patients receiving montelukast in Period II continued on montelukast in the Extension Study. One hundred sixty-seven patients were switched to the 5 mg chewable tablet at their first visit after turning 6 years old. The 4 mg and 5 mg chewable tablet data are pooled together."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "154"}, {"groupId": "OG001", "value": "357"}]}], "classes": [{"title": "With Drug-related LAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "7"}]}]}, {"title": "Without Drug-related LAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "154"}, {"groupId": "OG001", "value": "350"}]}]}]}, {"type": "SECONDARY", "title": "Number of Patients With Serious LAEs - Extension", "description": "Serious LAEs are any LAEs occurring at any dose that; Results in death; or Is life threatening; or Results in a persistent or significant disability/incapacity; or Results in or prolongs an existing inpatient hospitalization; or Is a congenital anomaly/birth defect; or Is a cancer; or Is an overdose", "populationDescription": "All patients who took study medication and had any laboratory tests performed were included in the analysis.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "up to 2.8 years", "groups": [{"id": "OG000", "title": "Usual Care", "description": "\"Usual care,\" defined as inhaled/nebulized cromolyn or inhaled/nebulized corticosteroids according to the usual clinical practice of the investigator, for up to 2.8 years. Some patients receiving placebo in Period II were switched to usual care in the Extension Study, and some patients receiving montelukast in Period II were switched to usual care in the Extension Study. Patients already using corticosteroids during Period I and II continued on the same medication and dose throughout Period II. Their dose was not increased if they were allocated to the \"usual care\" treatment group in Period III."}, {"id": "OG001", "title": "Montelukast", "description": "Extension Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for up to 2.8 years. Some patients receiving placebo in Period II were switched to montelukast in the Extension Study, and some patients receiving montelukast in Period II continued on montelukast in the Extension Study. One hundred sixty-seven patients were switched to the 5 mg chewable tablet at their first visit after turning 6 years old. The 4 mg and 5 mg chewable tablet data are pooled together."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "154"}, {"groupId": "OG001", "value": "357"}]}], "classes": [{"title": "With Serious LAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Without Serious LAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "154"}, {"groupId": "OG001", "value": "356"}]}]}]}, {"type": "SECONDARY", "title": "Number of Patients With Serious Drug-related Laboratory Adverse Experiences (LAEs) - Extension", "description": "Patients who reported serious drug-related LAEs up to 2.8 years of treatment", "populationDescription": "All patients who took study medication and had at least one laboratory test post baseline were included in the analysis.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "up to 2.8 years", "groups": [{"id": "OG000", "title": "Usual Care", "description": "\"Usual care,\" defined as inhaled/nebulized cromolyn or inhaled/nebulized corticosteroids according to the usual clinical practice of the investigator, for up to 2.8 years. Some patients receiving placebo in Period II were switched to usual care in the Extension Study, and some patients receiving montelukast in Period II were switched to usual care in the Extension Study. Patients already using corticosteroids during Period I and II continued on the same medication and dose throughout Period II. Their dose was not increased if they were allocated to the \"usual care\" treatment group in Period III."}, {"id": "OG001", "title": "Montelukast", "description": "Extension Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for up to 2.8 years. Some patients receiving placebo in Period II were switched to montelukast in the Extension Study, and some patients receiving montelukast in Period II continued on montelukast in the Extension Study. One hundred sixty-seven patients were switched to the 5 mg chewable tablet at their first visit after turning 6 years old. The 4 mg and 5 mg chewable tablet data are pooled together."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "154"}, {"groupId": "OG001", "value": "357"}]}], "classes": [{"title": "With Serious Drug-Related LAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Without Serious Drug-Related LAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "154"}, {"groupId": "OG001", "value": "356"}]}]}]}, {"type": "SECONDARY", "title": "Number of Patients Who Were Discontinued Due to LAEs - Extension", "description": "Patients who were discontinued due to LAEs up to 2.8 years of treatment", "populationDescription": "All patients who took study medication and had at least one laboratory test post baseline were included in the analysis.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "up to 2.8 years", "groups": [{"id": "OG000", "title": "Usual Care", "description": "\"Usual care,\" defined as inhaled/nebulized cromolyn or inhaled/nebulized corticosteroids according to the usual clinical practice of the investigator, for up to 2.8 years. Some patients receiving placebo in Period II were switched to usual care in the Extension Study, and some patients receiving montelukast in Period II were switched to usual care in the Extension Study. Patients already using corticosteroids during Period I and II continued on the same medication and dose throughout Period II. Their dose was not increased if they were allocated to the \"usual care\" treatment group in Period III."}, {"id": "OG001", "title": "Montelukast", "description": "Extension Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for up to 2.8 years. Some patients receiving placebo in Period II were switched to montelukast in the Extension Study, and some patients receiving montelukast in Period II continued on montelukast in the Extension Study. One hundred sixty-seven patients were switched to the 5 mg chewable tablet at their first visit after turning 6 years old. The 4 mg and 5 mg chewable tablet data are pooled together."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "154"}, {"groupId": "OG001", "value": "357"}]}], "classes": [{"title": "Discontinued Due to LAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "4"}]}]}, {"title": "Did Not Discontinue Due to LAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "154"}, {"groupId": "OG001", "value": "353"}]}]}]}, {"type": "SECONDARY", "title": "Number of Patients Who Were Discontinued Due to Drug-related LAEs - Extension", "description": "Patients who were discontinued due to drug-related LAEs with up to 2.8 years of treatment", "populationDescription": "All patients who took study medication and had at least one laboratory test post baseline were included in the analysis.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "up to 2.8 years", "groups": [{"id": "OG000", "title": "Usual Care", "description": "\"Usual care,\" defined as inhaled/nebulized cromolyn or inhaled/nebulized corticosteroids according to the usual clinical practice of the investigator, for up to 2.8 years. Some patients receiving placebo in Period II were switched to usual care in the Extension Study, and some patients receiving montelukast in Period II were switched to usual care in the Extension Study. Patients already using corticosteroids during Period I and II continued on the same medication and dose throughout Period II. Their dose was not increased if they were allocated to the \"usual care\" treatment group in Period III."}, {"id": "OG001", "title": "Montelukast", "description": "Base Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "154"}, {"groupId": "OG001", "value": "357"}]}], "classes": [{"title": "Discontinued Due to Drug-related LAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "4"}]}]}, {"title": "Did Not Discontinue Due to Drug-related LAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "154"}, {"groupId": "OG001", "value": "353"}]}]}]}, {"type": "SECONDARY", "title": "Number of Patients Who Were Discontinued Due to Serious LAEs - Extension", "description": "Patients who were discontinued due to serious LAEs with up to 2.8 years of treatment", "populationDescription": "All patients who took study medication and had at least one laboratory test post baseline were included in the analysis.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "up to 2.8 years", "groups": [{"id": "OG000", "title": "Usual Care", "description": "\"Usual care,\" defined as inhaled/nebulized cromolyn or inhaled/nebulized corticosteroids according to the usual clinical practice of the investigator, for up to 2.8 years. Some patients receiving placebo in Period II were switched to usual care in the Extension Study, and some patients receiving montelukast in Period II were switched to usual care in the Extension Study. Patients already using corticosteroids during Period I and II continued on the same medication and dose throughout Period II. Their dose was not increased if they were allocated to the \"usual care\" treatment group in Period III."}, {"id": "OG001", "title": "Montelukast", "description": "Extension Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for up to 2.8 years. Some patients receiving placebo in Period II were switched to montelukast in the Extension Study, and some patients receiving montelukast in Period II continued on montelukast in the Extension Study. One hundred sixty-seven patients were switched to the 5 mg chewable tablet at their first visit after turning 6 years old. The 4 mg and 5 mg chewable tablet data are pooled together."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "154"}, {"groupId": "OG001", "value": "357"}]}], "classes": [{"title": "Discontinued Due to Serious LAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Did Not Discontinue Due to Serious LAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "154"}, {"groupId": "OG001", "value": "356"}]}]}]}, {"type": "SECONDARY", "title": "Number of Patients Who Were Discontinued Due to Serious Drug-related LAEs - Extension", "description": "Patients who were discontinued due to serious drug-related LAEs with up to 2.8 years of treatment", "populationDescription": "All patients who took study medication and had at least one laboratory test post baseline were included in the analysis.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "up to 2.8 years", "groups": [{"id": "OG000", "title": "Usual Care", "description": "\"Usual care,\" defined as inhaled/nebulized cromolyn or inhaled/nebulized corticosteroids according to the usual clinical practice of the investigator, for up to 2.8 years. Some patients receiving placebo in Period II were switched to usual care in the Extension Study, and some patients receiving montelukast in Period II were switched to usual care in the Extension Study. Patients already using corticosteroids during Period I and II continued on the same medication and dose throughout Period II. Their dose was not increased if they were allocated to the \"usual care\" treatment group in Period III."}, {"id": "OG001", "title": "Montelukast", "description": "Extension Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for up to 2.8 years. Some patients receiving placebo in Period II were switched to montelukast in the Extension Study, and some patients receiving montelukast in Period II continued on montelukast in the Extension Study. One hundred sixty-seven patients were switched to the 5 mg chewable tablet at their first visit after turning 6 years old. The 4 mg and 5 mg chewable tablet data are pooled together."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "154"}, {"groupId": "OG001", "value": "357"}]}], "classes": [{"title": "Discontinued Due to Serious Drug-related LAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Not Discontinued Due to Serious Drug-related LAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "154"}, {"groupId": "OG001", "value": "356"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "During the 12 week base study (Period II) and 36 month extension study (Period III) and up to and including 14 days after the last dose of study therapy.", "description": "Although patient may have had 2 or more clinical adverse experiences, patient is counted only once in a category. The same patient may appear in different categories. Adverse events (AEs) in Period II have 0/0 for Usual Care group because there was no Usual Care group. AEs in Period III have 0/0 for Placebo group because there was no Placebo group.", "eventGroups": [{"id": "EG000", "title": "Placebo", "description": "Montelukast matching-image placebo chewable tablet orally once daily at bedtime for 12 weeks.", "seriousNumAffected": 9, "seriousNumAtRisk": 228, "otherNumAffected": 188, "otherNumAtRisk": 228}, {"id": "EG001", "title": "Usual Care", "description": "\"Usual care,\" defined as inhaled/nebulized cromolyn or inhaled/nebulized corticosteroids according to the usual clinical practice of the investigator, for up to 2.8 years. Some patients receiving placebo in Period II were switched to usual care in the Extension Study, and some\n\npatients receiving montelukast in Period II were switched to usual care in the Extension Study.\n\nPatients already using corticosteroids during Period I and II continued on the same medication and dose throughout Period II. Their dose was not increased if they were allocated to the \"usual care\" treatment group in Period III.", "seriousNumAffected": 15, "seriousNumAtRisk": 157, "otherNumAffected": 148, "otherNumAtRisk": 157}, {"id": "EG002", "title": "Montelukast", "description": "Base Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for 12 weeks.\n\nExtension Study - Montelukast 4 mg chewable tablet orally once daily at bedtime for up to 2.8 years. Some patients receiving placebo in Period II were switched to montelukast in the Extension Study, and some patients receiving montelukast in Period II continued on montelukast in the Extension Study. One hundred sixty-seven patients were switched to the 5 mg chewable tablet at\n\ntheir first visit after turning 6 years old. The 4 mg and 5 mg chewable tablet data are pooled together.", "seriousNumAffected": 56, "seriousNumAtRisk": 461, "otherNumAffected": 435, "otherNumAtRisk": 461}], "seriousEvents": [{"term": "Drug Overdose (Period II)", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 228}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 461}]}, {"term": "Drug Overdose (Period III)", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 9, "numAtRisk": 364}]}, {"term": "Infection, Viral (Period III)", "organSystem": "Infections and infestations", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 364}]}, {"term": "Pain, Abdominal (Period III)", "organSystem": "General disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 364}]}, {"term": "Trauma (Period III)", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 364}]}, {"term": "Tachycardia (Period III)", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 364}]}, {"term": "Appendicitis (Period III)", "organSystem": "Infections and infestations", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 364}]}, {"term": "Gastroenteritis (Period II)", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 228}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 461}]}, {"term": "Gastroenteritis, Infectious (Period III)", "organSystem": "Infections and infestations", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 364}]}, {"term": "Gastroesophageal Reflux (Period III)", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 364}]}, {"term": "Infection, Intra-Abdominal (Period III)", "organSystem": "Infections and infestations", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 364}]}, {"term": "Thirst (Period II)", "organSystem": "General disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 228}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 461}]}, {"term": "Thirst (Period III)", "organSystem": "General disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 364}]}, {"term": "Vomiting (Period III)", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 364}]}, {"term": "Alkaline Phosphatase Increased (Period III)", "organSystem": "Investigations", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 364}]}, {"term": "Allergy (Period III)", "organSystem": "Immune system disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 364}]}, {"term": "Dehydration (Period II)", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 228}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 461}]}, {"term": "Dehydration (Period III)", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 364}]}, {"term": "Hypokalemia (Period III)", "organSystem": "Investigations", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 364}]}, {"term": "Bipolar Disorder (Period II)", "organSystem": "Psychiatric disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 228}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 461}]}, {"term": "Concussion (Period III)", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 364}]}, {"term": "Headache (Period III)", "organSystem": "Nervous system disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 364}]}, {"term": "Hyperkinesia (Period III)", "organSystem": "Nervous system disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 364}]}, {"term": "Hypersomnia (Period III)", "organSystem": "Nervous system disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 364}]}, {"term": "Meningitis (Period III)", "organSystem": "Infections and infestations", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 364}]}, {"term": "Seizure Disorder (Period III)", "organSystem": "Nervous system disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 364}]}, {"term": "Somnolence (Period II)", "organSystem": "Nervous system disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 228}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 461}]}, {"term": "Somnolence (Period III)", "organSystem": "Nervous system disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 364}]}, {"term": "Tremor (Period III)", "organSystem": "Nervous system disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 364}]}, {"term": "Apnea (Period III)", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 364}]}, {"term": "Asthma (Period II)", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 228}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG002", "numAffected": 10, "numAtRisk": 461}]}, {"term": "Asthma (Period III)", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 8, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 13, "numAtRisk": 364}]}, {"term": "Bronchoconstriction (Period III)", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 364}]}, {"term": "Hypoxemia (Period III)", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 364}]}, {"term": "Infection, Respiratory, Upper (Period II)", "organSystem": "Infections and infestations", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 228}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 461}]}, {"term": "Infection, Respiratory, Upper (Period III)", "organSystem": "Infections and infestations", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 364}]}, {"term": "Infiltrate, Pulmonary (Period II)", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 228}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 461}]}, {"term": "Pneumonia (Period II)", "organSystem": "Infections and infestations", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 228}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 461}]}, {"term": "Pneumonia (Period III)", "organSystem": "Infections and infestations", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 364}]}, {"term": "Pneumonia, Bacterial (Period III)", "organSystem": "Infections and infestations", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 364}]}, {"term": "Pneumonia, Viral (Period III)", "organSystem": "Infections and infestations", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 364}]}, {"term": "Sinusitis (Period III)", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 364}]}, {"term": "Pallor (Period III)", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 364}]}, {"term": "Infection, Eyelid (Period III)", "organSystem": "Infections and infestations", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 364}]}, {"term": "Mydriasis (Period II)", "organSystem": "Eye disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 228}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 461}]}, {"term": "Anomaly, Urogenital (Period III)", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 364}]}], "otherEvents": [{"term": "Fever (Period II)", "organSystem": "General disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 61, "numAtRisk": 228}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG002", "numAffected": 125, "numAtRisk": 461}]}, {"term": "Fever (Period III)", "organSystem": "General disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 60, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 164, "numAtRisk": 364}]}, {"term": "Infection, Viral (Period III)", "organSystem": "Infections and infestations", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 25, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 55, "numAtRisk": 364}]}, {"term": "Pain, Abdominal (Period II)", "organSystem": "General disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 21, "numAtRisk": 228}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG002", "numAffected": 51, "numAtRisk": 461}]}, {"term": "Pain, Abdominal (Period III)", "organSystem": "General disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 16, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 46, "numAtRisk": 364}]}, {"term": "Trauma (Period III)", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 10, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 29, "numAtRisk": 364}]}, {"term": "Dental Caries (Period III)", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 10, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 12, "numAtRisk": 364}]}, {"term": "Diarrhea (Period II)", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 17, "numAtRisk": 228}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG002", "numAffected": 45, "numAtRisk": 461}]}, {"term": "Diarrhea (Period III)", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 28, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 58, "numAtRisk": 364}]}, {"term": "Gastroenteritis (Period III)", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 21, "numAtRisk": 364}]}, {"term": "Vomiting (Period II)", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 45, "numAtRisk": 228}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG002", "numAffected": 75, "numAtRisk": 461}]}, {"term": "Vomiting (Period III)", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 28, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 60, "numAtRisk": 364}]}, {"term": "Allergy (Period III)", "organSystem": "Immune system disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 22, "numAtRisk": 364}]}, {"term": "Headache (Period II)", "organSystem": "Nervous system disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 17, "numAtRisk": 228}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG002", "numAffected": 35, "numAtRisk": 461}]}, {"term": "Headache (Period III)", "organSystem": "Nervous system disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 26, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 57, "numAtRisk": 364}]}, {"term": "Asthma (Period II)", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 83, "numAtRisk": 228}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG002", "numAffected": 130, "numAtRisk": 461}]}, {"term": "Asthma (Period III)", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 96, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 217, "numAtRisk": 364}]}, {"term": "Bronchitis (Period II)", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 18, "numAtRisk": 228}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG002", "numAffected": 18, "numAtRisk": 461}]}, {"term": "Bronchitis (Period III)", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 38, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 58, "numAtRisk": 364}]}, {"term": "Congestion, Nasal (Period III)", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 11, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 30, "numAtRisk": 364}]}, {"term": "Cough (Period II)", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 26, "numAtRisk": 228}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG002", "numAffected": 58, "numAtRisk": 461}]}, {"term": "Cough (Period III)", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 24, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 97, "numAtRisk": 364}]}, {"term": "Epistaxis (Period III)", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 25, "numAtRisk": 364}]}, {"term": "Infection, Respiratory (Period II)", "organSystem": "Infections and infestations", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 13, "numAtRisk": 228}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG002", "numAffected": 19, "numAtRisk": 461}]}, {"term": "Infection, Respiratory (Period III)", "organSystem": "Infections and infestations", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 16, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 44, "numAtRisk": 364}]}, {"term": "Infection, Respiratory, Upper (Period II)", "organSystem": "Infections and infestations", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 63, "numAtRisk": 228}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG002", "numAffected": 123, "numAtRisk": 461}]}, {"term": "Infection, Respiratory, Upper (Period III)", "organSystem": "Infections and infestations", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 81, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 192, "numAtRisk": 364}]}, {"term": "Influenza (Period III)", "organSystem": "Infections and infestations", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 14, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 40, "numAtRisk": 364}]}, {"term": "Laryngitis (Period III)", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 8, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 22, "numAtRisk": 364}]}, {"term": "Pharyngitis (Period II)", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 35, "numAtRisk": 228}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG002", "numAffected": 54, "numAtRisk": 461}]}, {"term": "Pharyngitis (Period III)", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 50, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 120, "numAtRisk": 364}]}, {"term": "Pneumonia (Period III)", "organSystem": "Infections and infestations", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 21, "numAtRisk": 364}]}, {"term": "Rhinitis (Period II)", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 14, "numAtRisk": 228}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG002", "numAffected": 27, "numAtRisk": 461}]}, {"term": "Rhinitis (Period III)", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 21, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 45, "numAtRisk": 364}]}, {"term": "Rhinitis, Allergic (Period II)", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 16, "numAtRisk": 228}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG002", "numAffected": 24, "numAtRisk": 461}]}, {"term": "Rhinitis, Allergic (Period III)", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 13, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 40, "numAtRisk": 364}]}, {"term": "Rhinorrhea (Period II)", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 9, "numAtRisk": 228}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG002", "numAffected": 35, "numAtRisk": 461}]}, {"term": "Rhinorrhea (Period III)", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 16, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 32, "numAtRisk": 364}]}, {"term": "Sinus Disorder (Period III)", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 15, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 16, "numAtRisk": 364}]}, {"term": "Sinusitis (Period II)", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 16, "numAtRisk": 228}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG002", "numAffected": 33, "numAtRisk": 461}]}, {"term": "Sinusitis (Period III)", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 43, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 95, "numAtRisk": 364}]}, {"term": "Tonsillitis (Period II)", "organSystem": "Infections and infestations", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 15, "numAtRisk": 228}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG002", "numAffected": 12, "numAtRisk": 461}]}, {"term": "Tonsillitis (Period III)", "organSystem": "Infections and infestations", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 28, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 56, "numAtRisk": 364}]}, {"term": "Rash (Period III)", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 8, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 21, "numAtRisk": 364}]}, {"term": "Urticaria (Period III)", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 10, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 32, "numAtRisk": 364}]}, {"term": "Varicella (Period III)", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 20, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 45, "numAtRisk": 364}]}, {"term": "Conjunctivitis (Period III)", "organSystem": "Eye disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 9, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 32, "numAtRisk": 364}]}, {"term": "Otitis (Period II)", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 228}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG002", "numAffected": 29, "numAtRisk": 461}]}, {"term": "Otitis (Period III)", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 228}, {"groupId": "EG001", "numAffected": 33, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 62, "numAtRisk": 364}]}, {"term": "Otitis Media (Period II)", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 17, "numAtRisk": 228}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG002", "numAffected": 36, "numAtRisk": 461}]}, {"term": "Otitis Media (Period III)", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 35, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 84, "numAtRisk": 364}]}, {"term": "Pain, Ear (Period III)", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "CRISP dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numAffected": 10, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 25, "numAtRisk": 364}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp & Dohme Corp", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "C000093875", "term": "Montelukast"}], "ancestors": [{"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000020024", "term": "Leukotriene Antagonists"}, {"id": "D000006727", "term": "Hormone Antagonists"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000065694", "term": "Cytochrome P-450 CYP1A2 Inducers"}, {"id": "D000065693", "term": "Cytochrome P-450 Enzyme Inducers"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M274108", "name": "Montelukast", "asFound": "Conduction", "relevance": "HIGH"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M21876", "name": "Leukotriene Antagonists", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}